Bimekizumab versus Adalimumab in Plaque Psoriasis
نویسندگان
چکیده
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients moderate-to-severe plaque psoriasis have not been extensively examined.
منابع مشابه
Adalimumab: a new alternative biologic agent for chronic plaque psoriasis.
The results of a phase III European multicentre trial comparing adalimumab, placebo and methotrexate are published in this issue. An accompanying article examines the quality of life impacts derived from the same study. Adalimumab has been licensed for use in severe rheumatoid arthritis in combination with methotrexate and in psoriatic arthritis, ankylosing spondylitis and Crohn's disease. A li...
متن کاملAutoimmune hemolytic anemia during adalimumab treatment for plaque psoriasis.
Adalimumab is commonly used to treat autoimmune diseases with few reported hematological adverse reactions. We herein describe the case of an 85-year-old Japanese man with plaque psoriasis who developed autoimmune hemolytic anemia (AIHA) after 3 years of adalimumab treatment. The patient suddenly developed hematuria and dyspnea on exertion while receiving adalimumab treatment. Laboratory data s...
متن کاملVisual Loss Induced by Adalimumab Used for Plaque Psoriasis
A 61-year-old Caucasian male with severe plaque psoriasis without joint involvement was initiated on adalimumab therapy. Shortly thereafter he presented to the emergency room with acute loss of vision in the right eye. A comprehensive systemic workup was instituted which included magnetic resonance imaging (MRI) with and without gadolinium of the brain and orbits. MRI revealed findings that wer...
متن کاملTreating psoriasis with adalimumab
Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted. Recent advances in the understanding of the pathophysiology of psoriasis have led to the development of new, genetically engineered, targeted therapies for this disease. Among the most successful strategies for treatment has been the use of biologic imm...
متن کاملMethotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
BACKGROUND Methotrexate and cyclosporine are well-known systemic therapies for moderate-to-severe chronic plaque psoriasis. We conducted a randomized, controlled trial comparing methotrexate and cyclosporine in terms of effectiveness, side effects, and the quality of life. METHODS A total of 88 patients with moderate-to-severe psoriasis were randomly assigned to treatment for 16 weeks with ei...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The New England Journal of Medicine
سال: 2021
ISSN: ['0028-4793', '1533-4406']
DOI: https://doi.org/10.1056/nejmoa2102388